Celltrion Inc 068270
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 068270 is a good fit for your portfolio.
News
-
ZYMFENTRA™(infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, now commercially available in the U.S.
-
Celltrion USA completes submission of Biologics License Application (BLA) to U.S. FDA for CT-P39, an interchangeable biosimilar candidate of XOLAIR® (omalizumab)
-
Celltrion's Shares Climb After Merger With Affiliate
Trading Information
- Previous Close Price
- KRW 177,400.00
- Day Range
- KRW 176,300.00–178,800.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 177,400.00 / KRW 176,800.00
- Market Cap
- —
- Volume/Avg
- 221,176 / 633,703
Key Statistics
- Price/Earnings (Normalized)
- 46.24
- Price/Sales
- 11.64
- Dividend Yield (Trailing)
- 0.28%
- Dividend Yield (Forward)
- 0.28%
- Total Yield
- 2.73%
Company Profile
Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 2,277
- Website
- http://www.celltrion.com
Comparables
Valuation
|
Metric
|
068270
|
MRNA
|
002007
|
|---|---|---|---|
Price/Earnings (Normalized) | 46.24 | 40.19 | 26.80 |
Price/Book Value | 2.19 | 2.98 | 2.91 |
Price/Sales | 11.64 | 6.11 | 6.45 |
Price/Cash Flow | 35.34 | — | 32.96 |
Price/Earnings
068270
MRNA
002007
Financial Strength
|
Metric
|
068270
|
MRNA
|
002007
|
|---|---|---|---|
Quick Ratio | 0.70 | 3.21 | 2.68 |
Current Ratio | 2.03 | 3.42 | 4.01 |
Interest Coverage | 68.46 | −113.82 | 140.38 |
Quick Ratio
068270
MRNA
002007
Profitability
|
Metric
|
068270
|
MRNA
|
002007
|
|---|---|---|---|
Return on Assets (Normalized) | 5.99% | −20.12% | — |
Return on Equity (Normalized) | 8.07% | −26.85% | — |
Return on Invested Capital (Normalized) | 6.66% | −26.68% | — |
Return on Assets
068270
MRNA
002007
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vsjtnmbz | Fylg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jhzhwsv | Xjcyd | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tqkwhzzh | Ryrzl | $97.8 Bil | |
MRNA
| Moderna Inc | Wsmpbqqn | Zckb | $41.3 Bil | |
ARGX
| argenx SE ADR | Fjczmrzwc | Slgrs | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fnzdzlfvc | Mgq | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hymxscpf | Prpky | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nnqdvwpg | Flstwn | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ppkdxzglw | Hltbk | $12.5 Bil | |
INCY
| Incyte Corp | Fnzrfbgm | Pbztdlm | $11.6 Bil |